このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Shanghai Henlius Biotech マネジメント

マネジメント基準チェック /24

Shanghai Henlius Biotech'sの CEO はJason Zhuで、 May2023年に任命され、の在任期間は 1.08年です。の年間総報酬はCN¥ 9.26Mで、 87.8%給与と12.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.009%を直接所有しており、その価値はHK$ 942.03K 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と4.8年です。

主要情報

Jason Zhu

最高経営責任者

CN¥9.3m

報酬総額

CEO給与比率	87.8%
CEO在任期間	1.1yrs
CEOの所有権	0.009%
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	4.8yrs

経営陣の近況

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 22

CEO報酬分析

Shanghai Henlius Biotech の収益と比較して、Jason Zhu の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	CN¥9m	CN¥8m	CN¥546m

報酬と市場: Jasonの総報酬 ($USD 1.28M ) は、 Hong Kong市場 ($USD 501.01K ) の同規模の企業の平均を上回っています。

報酬と収益: Jasonの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Jason Zhu (45 yo)

1.1yrs

在職期間

CN¥9,261,000

報酬

Mr. Jun Zhu, also known as Jason, served as President at Shanghai Henlius Biotech, Inc. since November 30, 2021 until October 1, 2023 and its Chief Financial Officer since May 1, 2023 ands serves as its Ex...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Wenjie Zhang	Executive Chairman of the Board	4.4yrs	CN¥12.58m	データなし
Jun Zhu	CEO, CFO & Executive Director	1.1yrs	CN¥9.26m	0.0092% CN¥ 942.0k
Huang Wei	President	less than a year	データなし	データなし
Shi-Kau Liu	Co-founder & Head of Strategy Advisory Committee	14.3yrs	CN¥6.21m	0.44% CN¥ 45.4m
Wei-Dong Jiang	Co-Founder & Co-Head of Innovative Advisory Committee	14.3yrs	データなし	0.13% CN¥ 13.6m
Jifeng Zhang	CTO & Senior VP	1.5yrs	データなし	データなし
Miaojie Chen	Vice President of Legal & Compliance Department	1.4yrs	データなし	データなし
Wallis Zeng	VP of Sales & Oncology Business Unit	4.4yrs	データなし	データなし
Junhua Li	VP & Chief Human Resource Officer	2.2yrs	データなし	データなし
Xinjun Guo	Senior Vice President	no data	データなし	データなし
Kurt Yu	Senior VP & Chief Commercial Officer	3.4yrs	データなし	データなし
Cheng Yu	Chief Business Officer & Senior VP	2.6yrs	データなし	データなし

2.4yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: 2696の経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Wenjie Zhang	Executive Chairman of the Board	4.4yrs	CN¥12.58m	データなし
Jun Zhu	CEO, CFO & Executive Director	less than a year	CN¥9.26m	0.0092% CN¥ 942.0k
Tak Young So	Independent Non-Executive Director	4.8yrs	CN¥258.00k	データなし
Qiyu Chen	Non-Executive Director	11.4yrs	データなし	データなし
Guoping Zhao	Independent Non-Executive Director	4.8yrs	CN¥258.00k	データなし
Xiaohui Guan	Non-Executive Director	5.5yrs	データなし	データなし
K. Christopher Garcia	Member of Scientific Advisory Board	less than a year	データなし	データなし
Yifang Wu	Non-Executive Director	9yrs	データなし	データなし
Deyong Wen	Non-Executive Director	1.9yrs	データなし	データなし
Lik Yuen Chan	Independent Non-Executive Director	4.8yrs	CN¥258.00k	データなし
Ruilin Song	Independent Non-Executive Director	4.8yrs	CN¥258.00k	データなし
Rongli Feng	Chairman of Supervisory Board	4.2yrs	データなし	データなし

4.8yrs

平均在職期間

53yo

平均年齢

経験豊富なボード: 2696の取締役会は経験豊富であると考えられます ( 4.8年の平均在任期間)。

Shanghai Henlius Biotech マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Less than half of directors are independent

Shanghai Henlius Biotech, Inc. Announces Executive Changes

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA)

Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration

New major risk - Financial position

Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor)

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13

New minor risk - Financial position

Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023

Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND

Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022)

Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Consensus EPS estimates fall by 31%

Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx26

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Consensus revenue estimates increase by 13%

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces United States Food and Drug Administration Accepts the Biologic License Application for HLX02

Shanghai Henlius Biotech, Inc. Announces the First Patient in USA Has Been Dosed in Aninternational Multicentre Phase 3 Clinical Study Ofrecombinant Anti-Vegf Humanised Monoclonalantibody Ophthalmic Injection Hlx04-Ofor the Treatment of Wet Age-Related Maculardegeneration (Wamd)

Shanghai Henlius Biotech, Inc. Announces the Phase 1b/2 Clinical Trial of Hlx07

Shanghai Henlius Biotech, Inc. Announces Dosage of First Subject in Phase 1 Clinical Study of HLX15 (Recombinant Anti-CD38 Humanmonoclonal Antibody Injection) in Healthy Chinese Male Subjects

Shanghai Henlius Biotech, Inc. Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

Shanghai Henlius Biotech Announces the First Patient Dosage in the United States of America in an International Multi-Centre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection)

Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in A Phase 1 Clinical Trialof Hlx60 (Recombinant Humanized Anti-Garp Monoclonalantibody Injection) in Combination with Hansizhuang(Serplulimab Injection) for the Treatment of Advanced Ormetastatic Solid Tumors in Australia

Shanghai Henlius Biotech, Inc. Doses First Patient in A Phase 1 Clinical Trial of anti-TIGIT Fc Fusion Protein HLX53 for the Treatment of advanced/Metastatic Solid Tumours or Lymphomasin Mainland China

Shanghai Henlius Biotech, Inc. Announces the First Patient Was Dosed in NCT05468489

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Bridging Study Comparing Hansizhuang (Serplulimab Injection) Versus Atezolizumab

Shanghai Henlius Biotech, Inc. Announces Hansizhuang (Serplulimab Injection) in Combination with Chemotherapy and Concurrent Radiotherapy Approved to Commence A Phase 3 Clinical Trial

Less than half of directors are independent

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1b/2 Clinical Trial of HLX208

Shanghai Henlius Biotech, Inc. Receives Investigational New Drug Approval from China's National Medical Products Administration for A Phase 2 Clinical Trial of AC101

Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication Ofhansizhuang (Serplulimab Injection) in Combination Withchemotherapy for the First-Line Treatment of Squamousnon-Small Cell Lung Cancer Has Been Approved by Thenational Medical Products Administration

Shanghai Henlius Biotech, Inc. announces the Phase 2 Clinical Trial of Hlx22 in Combination Withhansizhuang (Serplulimab Injection) and Thestandard Therapy As the First-Line Treatment for Locally Advancedor Metastatic Gastric Cancer (Gc) Has Been Approvedby the National Medical Products Admin

Shanghai Henlius Biotech, Inc. Announces Approval of Hansizhuang (Serplulimab Injection) in Combination with Chemotherapy and Concurrent Radiotherapy to Commence A Phase 3 Clinical Trial for the Treatment of Limited-Stage Small Cell Lung Cancer in Australia

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Hlx60 for the Treatment of Solidtumours and Lymphomas Was Approved by the Nationalmedical Products Administration

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Hlx60 for the Treatment of Solidtumours and Lymphomas Was Approved by the Nationalmedical Products Administration

Shanghai Henlius Biotech, Inc. Announces Results of Phase 1 Clinical Trial Demonstrating Good Safety and Tolerability for HLX22 (Anti-Human Epidermal Growth Factor Receptor-2 (HER2) Humanised Monoclonal Antibody Injection) for the Treatment of HER2 Overexpressing Advanced Solid Tumours

マネジメント基準チェック /24